Drug intelligence / Profile preview

KP1020

Development stage: Unknown
Lead developer: 科越医药
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

**KP1020** is a bispecific monoclonal antibody developed by Kira Pharmaceuticals specifically for the treatment of dry age-related macular degeneration (dAMD). It targets complement pathways implicated in retinal inflammation and degeneration, leveraging a bispecific design to engage multiple complement components for enhanced therapeutic effect in this complement-driven ophthalmic disease. As an early-stage investigational biologic, it is part of Kira's broader complement-targeted pipeline focused on immune-mediated disorders.

Other names: KP1020/KP2050

Beyond the preview

Go deeper on KP1020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP1020.

Explore the full profile